NCT03841617 2026-02-17
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT03276988 2020-09-09
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
Genexine, Inc.
Phase 1/2 Completed
NCT02278198 2019-10-24
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
University of Colorado, Denver
Phase 1 Completed
NCT00196729 2015-03-18
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Sanofi
Phase 3 Completed
NCT00604318 2013-01-10
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
Copenhagen University Hospital at Herlev
Phase 4 Completed
NCT00001730 2008-03-04
Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
National Institutes of Health Clinical Center (CC)
Phase 4 Completed
NCT00435851 2007-02-19
Estimabl
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Unknown